Education
About Us
Working with TipRanks
Follow Us
BridgeBio Pharma Inc (BBIO)
NASDAQ:BBIO
Top Page
BridgeBio Pharma
(NASDAQ:BBIO)
Rating:58Neutral
Price Target:
$40.00
▲(0.88%Upside)
Positive Factors
Commercial Strategy
Attruby's strong 1Q sales were fueled by expansion of the ATTR-CM market, high fill rate of scripts, and BBIO's differentiated commercial strategy.
Regulatory Approvals
Acoramidis was approved as BEYONTTRA™ by the European Commission, the Japanese Ministry of Health, Labour, and Welfare (MHLW) Agency, and the United Kingdom Medicines and Healthcare Products Regulatory Agency, indicating strong regulatory support.
Sales Momentum
BridgeBio continues to report encouraging sales momentum, with 2,072 unique patient prescriptions written for acoramidis by 756 physicians.
Negative Factors
Competitive Pressure
Attruby's launch momentum in 1Q may decelerate in 2Q due to competitor Amvuttra's market entry and normalization of the script fill rate.
Market Competition
Amvuttra's entry is expected to negatively impact Attruby's uptake as suggested by Amvuttra's spiking weekly sales and Attruby's declined average scripts per week.
Market Dynamics
Attruby's launch momentum may decline due to increasing Amvuttra penetration.
BridgeBio Pharma (BBIO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.41B
Dividend YieldN/A
Average Volume (3M)2.80M
Price to Earnings (P/E)―
Beta (1Y)1.47
Revenue Growth-41.71%
EPS Growth-9.37%
CountryUS
Employees725
SectorHealthcare
Sector Strength55
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.88
Shares Outstanding189,880,720
10 Day Avg. Volume2,730,740
30 Day Avg. Volume2,799,594
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)-0.90
Price to Sales (P/S)0.00
P/FCF Ratio-2.64
Enterprise Value/Market Cap0.33
Enterprise Value/Revenue3.14
Enterprise Value/Gross Profit20.00
Enterprise Value/Ebitda-1.45
Forecast
1Y Price Target
$60.71Price Target Upside53.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
BridgeBio Pharma Business Overview & Revenue Model
Company DescriptionBridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
How the Company Makes MoneyBridgeBio Pharma makes money primarily through the development and commercialization of its pharmaceutical products. The company's revenue model is heavily reliant on advancing its drug candidates through clinical trials and obtaining regulatory approvals for them to be marketed. BridgeBio also enters into collaborations and strategic partnerships with other pharmaceutical companies and research institutions, which can involve milestone payments, licensing fees, and royalties. Additionally, the company may receive funding from investors to support its research and development activities and further expand its drug pipeline. These collaborations and partnerships are crucial as they provide both financial resources and expertise to accelerate the development and potential commercialization of its therapeutic candidates.
BridgeBio Pharma Earnings Call Summary
Earnings Call Date:Apr 29, 2025
(Q1-2025)
| % Change Since: 8.87%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
The earnings call was largely positive with the successful launch of Attruby driving significant revenue and the strong progress of the pipeline. While there were increased SG&A expenses due to the commercial rollout, the overall impact was minimal compared to the positive developments.Q1-2025 Updates
Positive Updates
Successful Attruby Launch
Attruby generated $36.7 million in revenue in its first quarter, with 2,072 unique patients receiving a prescription and 756 unique healthcare providers writing at least one prescription. The product demonstrated a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, including a 50% reduction in cardiovascular hospitalization.
Pipeline Progress
BridgeBio's pipeline includes three Phase 3 readouts expected in the next year, with trials in limb-girdle muscular dystrophy 2I, achondroplasia, and ADH1 on track. Additionally, the hypochondroplasia trial enrolled its first patient quickly, and positive POC data for encaleret in hypoparathyroidism was announced.
Financial Performance
Total revenues for Q1 2025 were $116.6 million, exceeding expectations. The company's NPV increased by 9% due to various factors, including better-than-anticipated revenue from Attruby and a successful convertible offering.
Strong Market Positioning
Attruby is positioned as the most cost-effective therapy in the ATTR-CM market, being 10% less expensive than tafamidis and 50% less expensive than vutrisiran. It also offers a free trial program for all patients and lifetime free drug for trial participants.
Negative Updates
Increased SG&A Expenses
SG&A expenses for Q1 2025 were $106.4 million, up from $65.8 million in the same period last year, due to the commercial rollout of Attruby, including field team deployment, payer engagement, and patient support infrastructure.
Impact of Tariffs
While tariffs had a negligible effect on overall NPV, they were mentioned as a factor affecting the company's financials, albeit insignificantly.
Company Guidance
During the Q1 2025 earnings call, BridgeBio provided guidance on several key metrics. The company reported $36.7 million in revenue from the launch of Attruby, emphasizing its clinical efficacy and cost-effectiveness. Attruby demonstrated a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, including a 50% reduction in cardiovascular hospitalization. BridgeBio's net present value (NPV) increased by 9% due to higher-than-expected revenue and early enrollment in trials, despite minor NPV drags from tariffs. The company is preparing for three Phase 3 readouts in the next year, expecting these developments to significantly impact their pipeline. BridgeBio maintains a focus on maximizing quality-adjusted life years for patients, striving for programs that are first-in-class or best-in-class, and ensuring each program is NPV positive.BridgeBio Pharma Financial Statement Overview
Summary
BridgeBio Pharma shows strong revenue growth but faces significant challenges in profitability and financial stability. The company operates with high leverage and negative equity, posing financial risks despite slight improvements in free cash flow.Income Statement
BridgeBio Pharma shows significant revenue growth in the TTM, but remains unprofitable with negative EBIT and EBITDA margins. The gross profit margin is relatively strong at 91.8%, yet the net profit margin is negative, indicating a struggle to convert revenue into profit.35
Negative
Balance Sheet
The balance sheet reveals a negative stockholders' equity, suggesting high financial leverage and potential insolvency risk. The debt-to-equity ratio is not meaningful due to negative equity, and the equity ratio is also negative, indicating liabilities exceed assets.20
Very Negative
Cash Flow
Operating cash flow is negative, but with a slight improvement in free cash flow in the TTM. The ratios of cash flows to net income are not favorable, reflecting ongoing cash burn issues.40
Negative
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 127.42M | 221.90M | 9.30M | 77.65M | 69.72M | 8.25M | Gross Profit |
| 123.53M | 218.02M | 6.86M | 74.21M | 66.60M | 5.16M | EBIT |
| -697.69M | -592.97M | -607.37M | -471.87M | -579.75M | -474.48M | EBITDA |
| -551.92M | -436.83M | -565.47M | -397.44M | -533.83M | -465.75M | Net Income Common Stockholders |
| -667.97M | -535.76M | -643.20M | -493.96M | -639.30M | -483.93M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 540.60M | 681.10M | 434.88M | 428.27M | 787.51M | 607.09M | Total Assets |
| 881.64M | 919.34M | 546.38M | 623.04M | 1.01B | 703.59M | Total Debt |
| 10.12M | 1.73B | 1.74B | 1.72B | 1.73B | 495.79M | Net Debt |
| -530.48M | 1.05B | 1.36B | 1.35B | 1.33B | 139.71M | Total Liabilities |
| 2.52B | 2.38B | 1.89B | 1.87B | 1.88B | 595.70M | Stockholders Equity |
| -1.64B | -1.46B | -1.35B | -1.25B | -870.41M | 57.91M |
| Cash Flow | Free Cash Flow | ||||
| -507.84M | -521.66M | -529.03M | -425.81M | -546.18M | -407.23M | Operating Cash Flow |
| -500.42M | -520.73M | -527.72M | -419.49M | -497.93M | -399.71M | Investing Cash Flow |
| 36.43M | 60.78M | 54.03M | 453.15M | -200.83M | -52.99M | Financing Cash Flow |
| 529.24M | 748.46M | 451.54M | -13.13M | 736.45M | 447.19M |
BridgeBio Pharma Technical Analysis
Positive
39.65
Price Trends
35.10
Positive
34.67
Positive
30.69
Positive
Market Momentum
1.32
Negative
67.17
Neutral
89.21
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BBIO, the sentiment is Positive. The current price of 39.65 is above the 20-day moving average (MA) of 35.64, above the 50-day MA of 35.10, and above the 200-day MA of 30.69, indicating a bullish trend. The MACD of 1.32 indicates Negative momentum. The RSI at 67.17 is Neutral, neither overbought nor oversold. The STOCH value of 89.21 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBIO.
BridgeBio Pharma Risk Analysis
BridgeBio Pharma disclosed 103 risk factors in its most recent earnings report. BridgeBio Pharma reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BridgeBio Pharma Peers Comparison
Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $6.08B | 153.16 | 19.70% | ― | 33.54% | -6.13% | |
58 Neutral | $7.41B | ― | 35.68% | ― | -41.71% | -9.37% | |
56 Neutral | $3.72B | 19.61 | -23.61% | ― | 59.15% | -1881.09% | |
54 Neutral | $5.38B | 3.31 | -45.11% | 3.29% | 16.82% | 0.04% | |
53 Neutral | $6.73B | ― | -20.00% | ― | 112.46% | 54.33% | |
52 Neutral | $7.82B | ― | -36.68% | ― | -100.00% | 5.49% | |
50 Neutral | $8.27B | ― | -47.71% | ― | 99.19% | 48.43% |
* Healthcare Sector Average
Performance Comparison
BBIO
BridgeBio Pharma
39.65
12.42
45.61%
SRPT
Sarepta Therapeutics
37.31
-79.52
-68.06%
TGTX
TG Therapeutics
36.01
19.44
117.32%
BPMC
Blueprint Medicines
128.21
24.34
23.43%
RVMD
Revolution Medicines
40.59
3.49
9.41%
LEGN
Legend Biotech
37.91
-3.59
-8.65%
BridgeBio Pharma Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
BridgeBio Pharma Appoints New President and CFO
Neutral
Mar 17, 2025
On March 17, 2025, BridgeBio Pharma announced the departure of its Chief Financial Officer, Brian C. Stephenson, who will transition to a consulting role until March 2026. Thomas Trimarchi, Ph.D., has been appointed as the new President and CFO, a move that positions the company to continue its focus on genetic diseases and potentially enhance its operational strategies.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.